{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:19:23Z","timestamp":1792210763055,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12072-015-9688-z","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T22:41:15Z","timestamp":1449787275000},"page":"377-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study"],"prefix":"10.1007","volume":"10","author":[{"given":"M.","family":"Assem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Elsabaawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Abdelrashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Elemam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Khodeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"El-Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,10]]},"reference":[{"key":"9688_CR1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.3748\/wjg.v18.i14.1700","volume":"18","author":"GN Kalambokis","year":"2012","unstructured":"Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin for the prevention of spontaneous bacterial peritonitis. World J Gastroenterol 2012;18:1700\u20131702","journal-title":"World J Gastroenterol"},{"key":"9688_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3748\/wjg.v17.i9.1091","volume":"17","author":"A Koulaouzidis","year":"2011","unstructured":"Koulaouzidis A. Diagnosis of spontaneous bacterial peritonitis: an update on leucocyte esterase reagent strips. World J Gastroenterol 2011;17:1091\u20131094","journal-title":"World J Gastroenterol"},{"key":"9688_CR3","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3748\/wjg.v17.i10.1237","volume":"17","author":"E Biecker","year":"2011","unstructured":"Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol 2011;17:1237\u20131248","journal-title":"World J Gastroenterol"},{"key":"9688_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/jhep.2002.30082","volume":"35","author":"J Fernandez","year":"2002","unstructured":"Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140\u2013148","journal-title":"Hepatology"},{"key":"9688_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/MOG.0b013e328333dc8d","volume":"26","author":"HL Koo","year":"2010","unstructured":"Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010;26:17\u201325","journal-title":"Curr Opin Gastroenterol"},{"key":"9688_CR6","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/j.1365-2036.2009.03958.x","volume":"29","author":"J Vlachogiannakos","year":"2009","unstructured":"Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009;29:992\u2013999","journal-title":"Aliment Pharmacol Ther"},{"key":"9688_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/jgh.12070","volume":"28","author":"J Vlachogiannakos","year":"2013","unstructured":"Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013;28:450\u2013455","journal-title":"J Gastroenterol Hepatol"},{"key":"9688_CR8","doi-asserted-by":"publisher","first-page":"e1002105","DOI":"10.1371\/journal.pbio.1002105","volume":"13","author":"L Richardson","year":"2015","unstructured":"Richardson L. Alternating antibiotics render resistant bacteria beatable. PLoS Biol 2015;13:e1002105","journal-title":"PLoS Biol"},{"key":"9688_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.dld.2013.07.015","volume":"46","author":"S Fagiuoli","year":"2014","unstructured":"Fagiuoli S, Colli A, Bruno R, Burra P, Craxi A, Gaeta GB, et al. Management of infections in cirrhotic patients: report of a consensus conference. Dig Liver Dis 2014;46:204\u2013212","journal-title":"Dig Liver Dis"},{"key":"9688_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","volume":"64","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015;64:531\u2013537","journal-title":"Gut"},{"key":"9688_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.510230122","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164\u2013176","journal-title":"Hepatology"},{"key":"9688_CR12","first-page":"1310","volume":"56","author":"F Salerno","year":"2007","unstructured":"Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310\u20131318","journal-title":"Gut"},{"key":"9688_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/gut.2006.113050","volume":"56","author":"SH Sigal","year":"2007","unstructured":"Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007;56:597\u2013599","journal-title":"Gut"},{"key":"9688_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM199908053410603","volume":"341","author":"P Sort","year":"1999","unstructured":"Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403\u2013409","journal-title":"N Engl J Med"},{"key":"9688_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/j.1572-0241.1998.00288.x","volume":"93","author":"WJ Hsieh","year":"1998","unstructured":"Hsieh WJ, Lin HC, Hwang SJ, Hou MC, Lee FY, Chang FY, et al. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol 1998;93:962\u2013966","journal-title":"Am J Gastroenterol"},{"key":"9688_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00535-011-0485-8","volume":"47","author":"Y Narahara","year":"2012","unstructured":"Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, et al. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol 2012;47:313\u2013320","journal-title":"J Gastroenterol"},{"key":"9688_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","volume":"33","author":"J Uriz","year":"2000","unstructured":"Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43\u201348","journal-title":"J Hepatol"},{"key":"9688_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","volume":"133","author":"J Fernandez","year":"2007","unstructured":"Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818\u2013824","journal-title":"Gastroenterology"},{"key":"9688_CR19","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/0016-5085(86)90185-X","volume":"91","author":"BA Runyon","year":"1986","unstructured":"Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986;91:1343\u20131346","journal-title":"Gastroenterology"},{"key":"9688_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1053\/gast.1999.0029900414","volume":"117","author":"C Guarner","year":"1999","unstructured":"Guarner C, Sola R, Soriano G, Andreu M, Novella MT, Vila MC, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999;117:414\u2013419","journal-title":"Gastroenterology"},{"key":"9688_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hep.1840160318","volume":"16","author":"J Llach","year":"1992","unstructured":"Llach J, Rimola A, Navasa M, Gines P, Salmeron JM, Gines A, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992;16:724\u2013747","journal-title":"Hepatology"},{"key":"9688_CR22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0016-5085(93)90284-J","volume":"104","author":"M Andreu","year":"1993","unstructured":"Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133\u20131138","journal-title":"Gastroenterology"},{"key":"9688_CR23","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/hep.1840200619","volume":"20","author":"A Follo","year":"1994","unstructured":"Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495\u20131501","journal-title":"Hepatology"},{"key":"9688_CR24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","volume":"105","author":"A Gines","year":"1993","unstructured":"Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229\u2013236","journal-title":"Gastroenterology"},{"key":"9688_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1055\/s-2007-1007201","volume":"17","author":"R Bataller","year":"1997","unstructured":"Bataller R, Gines P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997;17:233\u2013247","journal-title":"Semin Liver Dis"},{"key":"9688_CR26","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/hep.21412","volume":"44","author":"P Angeli","year":"2006","unstructured":"Angeli P, Wong F, Watson H, Gines P, Investigators C. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535\u20131542","journal-title":"Hepatology"},{"key":"9688_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0168-8278(00)80201-9","volume":"32","author":"A Rimola","year":"2000","unstructured":"Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142\u2013153","journal-title":"J Hepatol"},{"key":"9688_CR28","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/hep.20066","volume":"39","author":"BA Runyon","year":"2004","unstructured":"Runyon BA. Practice Guidelines Committee AASLD. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841\u2013856","journal-title":"Hepatology"},{"key":"9688_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1053\/jhep.2003.50315","volume":"38","author":"KP Moore","year":"2003","unstructured":"Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258\u2013266","journal-title":"Hepatology"},{"issue":"Suppl 6","key":"9688_CR30","first-page":"vi1","volume":"55","author":"KP Moore","year":"2006","unstructured":"Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55(Suppl 6):vi1\u201312","journal-title":"Gut"},{"key":"9688_CR31","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.3748\/wjg.15.3845","volume":"15","author":"O Riggio","year":"2009","unstructured":"Riggio O, Angeloni S. Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis. World J Gastroenterol 2009;15:3845\u20133850","journal-title":"World J Gastroenterol"},{"key":"9688_CR32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1053\/j.gastro.2007.07.017","volume":"133","author":"BA Runyon","year":"2007","unstructured":"Runyon BA. A pill a day can improve survival in patients with advanced cirrhosis. Gastroenterology 2007;133:1029\u20131031","journal-title":"Gastroenterology"},{"key":"9688_CR33","doi-asserted-by":"crossref","unstructured":"Sandhu BS, Sanyal AJ. Management of ascites in cirrhosis. Clin Liver Dis 2005;9:715\u2013732, viii","DOI":"10.1016\/j.cld.2005.07.008"},{"key":"9688_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1128\/AAC.38.2.340","volume":"38","author":"C Dupeyron","year":"1994","unstructured":"Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994;38:340\u2013344","journal-title":"Antimicrob Agents Chemother"},{"key":"9688_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/MCG.0b013e3182506dbb","volume":"46","author":"MA Hanouneh","year":"2012","unstructured":"Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, Lopez R, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012;46:709\u2013715","journal-title":"J Clin Gastroenterol"},{"key":"9688_CR36","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/j.1469-0691.2004.00997.x","volume":"10","author":"HL DuPont","year":"2004","unstructured":"DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect 2004;10:1009\u20131011","journal-title":"Clin Microbiol Infect"},{"key":"9688_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.7326\/0003-4819-142-10-200505170-00005","volume":"142","author":"HL DuPont","year":"2005","unstructured":"DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers\u2019 diarrhea. Ann Intern Med 2005;142:805\u2013812","journal-title":"Ann Intern Med"},{"key":"9688_CR38","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1128\/AAC.00161-10","volume":"54","author":"C Darkoh","year":"2010","unstructured":"Darkoh C, Lichtenberger LM, Ajami N, Dial EJ, Jiang ZD, DuPont HL. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother 2010;54:3618\u20133624","journal-title":"Antimicrob Agents Chemother"},{"key":"9688_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5152\/tjg.2015.7782","volume":"26","author":"T Mostafa","year":"2015","unstructured":"Mostafa T, Badra G, Abdallah M. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients. Turk J Gastroenterol 2015;26:163\u2013169","journal-title":"Turk J Gastroenterol"},{"key":"9688_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7326\/0003-4819-139-3-200308050-00008","volume":"139","author":"B Rasaratnam","year":"2003","unstructured":"Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003;139:186\u2013193","journal-title":"Ann Intern Med"},{"key":"9688_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1053\/jhep.2003.50038","volume":"37","author":"A Albillos","year":"2003","unstructured":"Albillos A, de la Hera A, Gonzalez M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208\u2013217","journal-title":"Hepatology"},{"key":"9688_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/hep.20766","volume":"42","author":"L Ruiz-del-Arbol","year":"2005","unstructured":"Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439\u2013447","journal-title":"Hepatology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-015-9688-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9688-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:17:57Z","timestamp":1659097077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-015-9688-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["9688"],"URL":"https:\/\/doi.org\/10.1007\/s12072-015-9688-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,10]]},"assertion":[{"value":"28 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All participating centers shared in the fund.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Assem, M. Elsabaawy,\n M. Abdelrashed, S. Elemam, S. Khodeer,\nW. Hamed, A. Abdelaziz, G. El-Azab  declare no competing interests, either financial or non-financial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the local ethics committee at each participating center and written informed consent was obtained from patients before entering the study. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}